NCT Number: NCT02289846
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
The objectives of this study are to evaluate the safety of IW-9179 in patients with diabetic gastroparesis (DGP) and the effect of treatment on the cardinal symptoms of DGP.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Ironwood Investigational Site, Birmingham, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient is a male or non-pregnant, non-breastfeeding female, and is age 18 years or older at the time of the Screening Visit.
- Patient has a confirmed diagnosis of type 1 or type 2 diabetes mellitus.
- Patient has a diagnosis of DGP with no history or evidence of mechanical obstruction, symptoms for at least 3 consecutive months preceding the Screening Visit, and delayed gastric emptying of solids documented within 2 years of the Screening Visit.
- Patient has a normal EGD either during the Screening Period or within 2 years of the Screening Visit, with no evidence of structural or organic disease that may explain the patient's gastroduodenal symptoms.
- Patient is compliant with eDiary completion.
- Patient agrees to refrain from making any new, major lifestyle changes.
- Patient is fluent and literate in English.
Exclusion criteria
- Patient has a history or current symptoms of any organic or structural disease that, in the opinion of the investigator, can cause abdominal pain or discomfort and may confound the assessment of DGP symptoms.
- Patients with rumination syndrome, cyclic vomiting syndrome, anorexia nervosa, or bulimia.
- Patient is currently using a gastric electric stimulator or has had endoscopic pyloric injections of botulinum toxin within the 6 months prior to the Screening Visit.
- Patient has been hospitalized within the 2 months prior to the Screening Visit for uncontrolled diabetes mellitus, DGP, or associated malnutrition.
- Patient reports significant diarrhea during the four weeks prior to the Screening Visit, or more than 2 days during either week of the Pretreatment Period.
- Patient has had surgery of the GI tract any time before the Screening Visit, an appendectomy or cholecystectomy during the 3 months before the Screening Visit, non-GI surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months, or other major non-GI surgery during the 30 days before the Screening Visit.
- Patient has a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable).
Treatment and study plan
Matching Placebo
DrugPrimary outcomes
-
Exploratory Endpoint - Daily Severity of Patient-reported Diabetic Gastroparesis Symptoms
Time frame: Change from baseline: Treatment Period (weeks 1-4) compared with 2-week (baseline) Pretreatment Period
Sponsors and collaborators
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Registry information
Official study title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Important dates
- Study start
- 2014
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Nov 13, 2014
- Registry last updated
- Dec 5, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Biomagnetic Characterization of Gastric Dysrhythmias III
NCT03176927
Chronic Nausea, Diabetic Gastroparesis
Nashville, Tennessee, United States
View Trial DetailsA Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Diabetic Gastroparesis, Digestive System Diseases
Dothan, Alabama, United States
View Trial DetailsA Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
NCT04303195
Diabetic Gastroparesis, Idiopathic Gastroparesis
Dothan, Alabama, United States
View Trial DetailsEvaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
NCT04028492
Diabetic Gastroparesis, Digestive System Diseases
Birmingham, Alabama, United States
View Trial Details